Non-Antibiotic Antibacterial Agents: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Jan Paczesny.

Antimicrobial resistance is a significant threat to human health worldwide, forcing scientists to explore non-traditional antibacterial agents to support rapid interventions and combat the emergence and spread of drug resistant bacteria. Many new antibiotic-free approaches are being developed while the old ones are being revised, resulting in creating unique solutions that arise at the interface of physics, nanotechnology, and microbiology. Specifically, physical factors (e.g., pressure, temperature, UV light) are increasingly used for industrial sterilization. Nanoparticles (unmodified or in combination with toxic compounds) are also applied to circumvent in vivo drug resistance mechanisms in bacteria. Recently, bacteriophage-based treatments are also gaining momentum due to their high bactericidal activity and specificity. 

  • antimicrobial resistance
  • antibacterial agents
  • nanoparticles
  • bacteriophages
Please wait, diff process is still running!

References

  1. Pelfrene, E.; Botgros, R.; Cavaleri, M. Antimicrobial multidrug resistance in the era of COVID-19: A forgotten plight? Antimicrob. Resist. Infect. Control 2021, 10, 1–6.
  2. Capita, R.; Alonso-Calleja, C. Antibiotic-Resistant Bacteria: A Challenge for the Food Industry. Crit. Rev. Food Sci. Nutr. 2013, 53, 11–48.
  3. Nji, E.; Kazibwe, J.; Hambridge, T.; Joko, C.A.; Larbi, A.A.; Damptey, L.A.O.; Nkansa-Gyamfi, N.A.; Stålsby Lundborg, C.; Lien, L.T.Q. High prevalence of antibiotic resistance in commensal Escherichia coli from healthy human sources in community settings. Sci. Rep. 2021, 11, 1–11.
  4. Neill, J.O. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. In Review on Antimicrobial Resistance Chaired; Wellcome Trust: UK, London, 2014.
  5. Smith, M. Antibiotic Resistance Mechanisms. Journeys Med. Res. Three Cont. Over 2017, 95–99.
  6. Ventola, C.L. The antibiotic resistance crisis: Part 1: Causes and threats. Pharm. Ther. 2015, 40, 277–283.
  7. Wang, W.; Arshad, M.I.; Khurshid, M.; Rasool, M.H.; Nisar, M.A.; Aslam, M.A.; Qamar, M.U. Antibiotic resistance: A rundown of a global crisis. Infect. Drug Resist. 2018, 11, 1645–1658.
  8. Liu, Y.-Y.; Wang, Y.; Walsh, T.R.; Yi, L.-X.; Zhang, R.; Spencer, J.; Doi, Y.; Tian, G.; Dong, B.; Huang, X.; et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect. Dis. 2015.
  9. Wang, R.; Van Dorp, L.; Shaw, L.P.; Bradley, P.; Wang, Q.; Wang, X.; Jin, L.; Zhang, Q.; Liu, Y.; Rieux, A.; et al. The global distribution and spread of the mobilized colistin resistance gene mcr-1. Nat. Commun. 2018, 9, 1–9.
  10. Otto, C.; Zahn, S.; Rost, F.; Zahn, P.; Jaros, D.; Rohm, H. Physical Methods for Cleaning and Disinfection of Surfaces. Food Eng. Rev. 2011, 3, 171–188.
  11. Theuretzbacher, U.; Piddock, L.J.V. Non-traditional Antibacterial Therapeutic Options and Challenges. Cell Host Microbe 2019, 26, 61–72.
  12. Beyth, N.; Houri-Haddad, Y.; Domb, A.; Khan, W.; Hazan, R. Alternative antimicrobial approach: Nano-antimicrobial materials. Evid. Based Complement. Altern. Med. 2015, 2015.
  13. Wybrańska, K.; Paczesny, J.; Serejko, K.; Sura, K.; Włodyga, K.; Dzięcielewski, I.; Jones, S.T.; Sliwa, A.; Wybrańska, I.; Hołyst, R.; et al. Gold-oxoborate nanocomposites and their biomedical applications. ACS Appl. Mater. Interfaces 2015, 7, 3931–3939.
  14. Tripathy, A.; Sen, P.; Su, B.; Briscoe, W.H. Natural and bioinspired nanostructured bactericidal surfaces. Adv. Colloid Interface Sci. 2017, 248, 85–104.
  15. Pillai, P.P.; Kowalczyk, B.; Kandere-Grzybowska, K.; Borkowska, M.; Grzybowski, B.A. Engineering Gram Selectivity of Mixed-Charge Gold Nanoparticles by Tuning the Balance of Surface Charges. Angew. Chemie Int. Ed. 2016, 55, 8610–8614.
  16. Vallet-Regí, M.; González, B.; Izquierdo-Barba, I. Nanomaterials as promising alternative in the infection treatment. Int. J. Mol. Sci. 2019, 20, 3806.
  17. Sulakvelidze, A.; Alavidze, Z.J.; Glenn Morris, J. Bacteriophage Therapy. Antimicrob. Agents Chemother. 2001, 45, 649–659.
  18. Parfitt, T. Georgia: An unlikely stronghold for bacteriophage therapy. Lancet 2005, 365, 2166–2167.
  19. Abedon, S.T.; Kuhl, S.J.; Blasdel, B.G.; Kutter, E.M. Phage treatment of human infections. Bacteriophage 2011, 1, 66–85.
  20. McCallin, S.; Alam Sarker, S.; Barretto, C.; Sultana, S.; Berger, B.; Huq, S.; Krause, L.; Bibiloni, R.; Schmitt, B.; Reuteler, G.; et al. Safety analysis of a Russian phage cocktail: From MetaGenomic analysis to oral application in healthy human subjects. Virology 2013, 443, 187–196.
  21. Novickij, V.; Stanevičiene, R.; Vepštaite-Monstaviče, I.; Gruškiene, R.; Krivorotova, T.; Sereikaite, J.; Novickij, J.; Serviene, E. Overcoming antimicrobial resistance in bacteria using bioactive magnetic nanoparticles and pulsed electromagnetic fields. Front. Microbiol. 2018, 8, 1–8.
  22. Sun, W.; Qian, X.; Gu, J.; Wang, X.J.; Duan, M.L. Mechanism and Effect of Temperature on Variations in Antibiotic Resistance Genes during Anaerobic Digestion of Dairy Manure. Sci. Rep. 2016, 6, 1–9.
  23. Li, H.; Gänzle, M. Some like it hot: Heat resistance of Escherichia coli in food. Front. Microbiol. 2016, 7, 1–12.
  24. Loraine, G.; Chahine, G.; Hsiao, C.T.; Choi, J.K.; Aley, P. Disinfection of gram-negative and gram-positive bacteria using DynaJets® hydrodynamic cavitating jets. Ultrason. Sonochem. 2012, 19, 710–717.
  25. Mai-Prochnow, A.; Clauson, M.; Hong, J.; Murphy, A.B. Gram positive and Gram negative bacteria differ in their sensitivity to cold plasma. Sci. Rep. 2016, 6, 1–11.
  26. Cebrián, G.; Condón, S.; Mañas, P. Physiology of the Inactivation of Vegetative Bacteria by Thermal Treatments: Mode of Action, Influence of Environmental Factors and Inactivation Kinetics. Foods 2017, 6, 107.
  27. Yoon, Y.; Lee, H.; Lee, S.; Kim, S.; Choi, K.H. Membrane fluidity-related adaptive response mechanisms of foodborne bacterial pathogens under environmental stresses. Food Res. Int. 2015, 72, 25–36.
  28. Cebrián, G.; Mañas, P.; Condón, S. Comparative resistance of bacterial foodborne pathogens to non-thermal technologies for food preservation. Front. Microbiol. 2016, 7, 1–17.
  29. René, O.; Alix, J.H. Late steps of ribosome assembly in E. coli are sensitive to a severe heat stress but are assisted by the HSP70 chaperone machine. Nucleic Acids Res. 2011, 39, 1855–1867.
  30. Guyot, S.; Pottier, L.; Ferret, E.; Gal, L.; Gervais, P. Physiological responses of Escherichia coli exposed to different heat-stress kinetics. Arch. Microbiol. 2010, 192, 651–661.
  31. Szeto, W.; Yam, W.C.; Huang, H.; Leung, D.Y.C. The efficacy of vacuum-ultraviolet light disinfection of some common environmental pathogens. BMC Infect. Dis. 2020, 20, 1–9.
  32. Maclean, M.; MacGregor, S.J.; Anderson, J.G.; Woolsey, G. Inactivation of bacterial pathogens following exposure to light from a 405-nanometer light-emitting diode array. Appl. Environ. Microbiol. 2009, 75, 1932–1937.
  33. Kovach, C.R.; Taneli, Y.; Neiman, T.; Dyer, E.M.; Arzaga, A.J.A.; Kelber, S.T. Evaluation of an ultraviolet room disinfection protocol to decrease nursing home microbial burden, infection and hospitalization rates. BMC Infect. Dis. 2017, 17, 1–8.
  34. Silva, J.; Castillo, G.; Callejas, L.; López, H.; Olmos, J. Frequency of transferable multiple antibiotic resistance amongst coliform bacteria isolated from a treated sewage effluent in Antofagasta, Chile. Electron. J. Biotechnol. 2006, 9, 533–540.
  35. Lamprecht-Grandío, M.; Cortesão, M.; Mirete, S.; de la Cámara, M.B.; de Figueras, C.G.; Pérez-Pantoja, D.; White, J.J.; Farías, M.E.; Rosselló-Móra, R.; González-Pastor, J.E. Novel Genes Involved in Resistance to both Ultraviolet Radiation and Perchlorate from the Metagenomes of Hypersaline Environments. Front. Microbiol. 2020, 11, 1–15.
  36. Mofidi, A.A.; Rochelle, P.A.; Chou, C.I.; Mehta, H.M.; Verne, L.; Linden, K.G. Bacterial Survival After Ultraviolet Light Disinfection: Resistance, Regrowth and Repair. Am. Water Work. Assoc. Annu. Conf. Exhib. 2002, 1–11.
  37. Pérez, V.; Hengst, M.; Kurte, L.; Dorador, C.; Jeffrey, W.H.; Wattiez, R.; Molina, V.; Matallana-Surget, S. Bacterial survival under extreme UV radiation: A comparative proteomics study of Rhodobacter sp., isolated from high altitude wetlands in Chile. Front. Microbiol. 2017, 8, 1–16.
  38. Alcántara-Díaz, D.; Breña-Valle, M.; Serment-Guerrero, J. Divergent adaptation of Escherichia coli to cyclic ultraviolet light exposures. Mutagenesis 2004, 19, 349–354.
  39. Marizcurrena, J.J.; Morel, M.A.; Braña, V.; Morales, D.; Martinez-López, W.; Castro-Sowinski, S. Searching for novel photolyases in UVC-resistant Antarctic bacteria. Extremophiles 2017, 21, 409–418.
  40. Monsalves, M.T.; Ollivet-Besson, G.P.; Amenabar, M.J.; Blamey, J.M. Isolation of a psychrotolerant and UV-C-resistant bacterium from elephant island, antarctica with a highly thermoactive and thermostable catalase. Microorganisms 2020, 8, 95.
  41. Díaz-Riaño, J.; Posada, L.; Acosta, I.C.; Ruíz-Pérez, C.; García-Castillo, C.; Reyes, A.; Zambrano, M.M. Computational search for UV radiation resistance strategies in Deinococcus swuensis isolated from Paramo ecosystems. PLoS ONE 2019, 14, 1–17.
  42. Moreirinha, C.; Almeida, A.; Saraiva, J.A.; Delgadillo, I. High-pressure processing effects on foodborne bacteria by mid-infrared spectroscopy analysis. LWT Food Sci. Technol. 2016, 73, 212–218.
  43. Chikuma, S.; Kasahara, R.; Kato, C.; Tamegai, H. Bacterial adaptation to high pressure: A respiratory system in the deep-sea bacterium Shewanella violacea DSS12. FEMS Microbiol. Lett. 2007, 267, 108–112.
  44. Masson, P.; Tonello, C.; Balny, C. High-pressure biotechnology in medicine and pharmaceutical science. J. Biomed. Biotechnol. 2001, 2001, 85–88.
  45. Yoo, J.H. Review of disinfection and sterilization—Back to the basics. Infect. Chemother. 2018, 50, 101–109.
  46. Reineke, K.; Mathys, A.; Knorr, D. The impact of high pressure and temperature on bacterial spores: Inactivation mechanisms of Bacillus subtilis above 500 MPa. J. Food Sci. 2011, 76.
  47. Vanlint, D.; Rutten, N.; Michiels, C.W.; Aertsen, A. Emergence and stability of high-pressure resistance in different food-borne pathogens. Appl. Environ. Microbiol. 2012, 78, 3234–3241.
  48. Mota, M.J.; Lopes, R.P.; Delgadillo, I.; Saraiva, J.A. Microorganisms under high pressure—Adaptation, growth and biotechnological potential. Biotechnol. Adv. 2013, 31, 1426–1434.
  49. Pudasaini, S.; Perera, A.T.K.; Ng, S.H.; Yang, C. Bacterial inactivation via microfluidic electroporation device with insulating micropillars. Electrophoresis 2021, 1–9.
  50. Kotnik, T.; Frey, W.; Sack, M.; Haberl Meglič, S.; Peterka, M.; Miklavčič, D. Electroporation-based applications in biotechnology. Trends Biotechnol. 2015, 33, 480–488.
  51. Martens, S.L.; Klein, S.; Barnes, R.A.; TrejoSanchez, P.; Roth, C.C.; Ibey, B.L. 600-ns pulsed electric fields affect inactivation and antibiotic susceptibilities of Escherichia coli and Lactobacillus acidophilus. AMB Express 2020, 10.
  52. Escoffre, J.M.; Portet, T.; Wasungu, L.; Teissié, J.; Dean, D.; Rols, M.P. What is (Still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues. Mol. Biotechnol. 2009, 41, 286–295.
  53. Garcia, P.A.; Ge, Z.; Moran, J.L.; Buie, C.R. Microfluidic screening of electric fields for electroporation. Sci. Rep. 2016, 6, 1–11.
  54. Cannon, R.; Ellis, S.; Hayes, D.; Narayanan, G.; Martin, R.C.G. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J. Surg. Oncol. 2013, 107, 544–549.
  55. Pillet, F.; Formosa-Dague, C.; Baaziz, H.; Dague, E.; Rols, M.P. Cell wall as a target for bacteria inactivation by pulsed electric fields. Sci. Rep. 2016, 6, 1–8.
  56. Costello, S.R. Effect of Electric Field on Growth Kinetics of Yogurt Starter Cultures, Lactobacillus Bulgaricus and Streptococcus Thermophilus. Master’s Thesis, The Ohio State University, Columbus, OH, USA, 2012.
  57. Gall, I.; Herzberg, M.; Oren, Y. The effect of electric fields on bacterial attachment to conductive surfaces. Soft Matter 2013, 9, 2443–2452.
  58. Yonemoto, Y.; Yamashita, T.; Muraji, M.; Tatebe, W.; Ooshima, H.; Kato, J.; Kimura, A.; Murata, K. Resistance of yeast and bacterial spores to high voltage electric pulses. J. Ferment. Bioeng. 1993, 75, 99–102.
  59. Puligundla, P.; Pyun, Y.R.; Mok, C. Pulsed electric field (PEF) technology for microbial inactivation in low-alcohol red wine. Food Sci. Biotechnol. 2018, 27, 1691–1696.
  60. Makabenta, J.M.V.; Nabawy, A.; Li, C.H.; Schmidt-Malan, S.; Patel, R.; Rotello, V.M. Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. Nat. Rev. Microbiol. 2020.
  61. Pelgrift, R.Y.; Friedman, A.J. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv. Drug Deliv. Rev. 2013, 65, 1803–1815.
  62. Stark, W.J. Nanoparticles in biological systems. Angew. Chemie Int. Ed. 2011, 50, 1242–1258.
  63. Doane, T.; Burda, C. Nanoparticle mediated non-covalent drug delivery. Adv. Drug Deliv. Rev. 2013, 65, 607–621.
  64. Limbach, L.K.; Li, Y.; Grass, R.N.; Brunner, T.J.; Hintermann, M.A.; Muller, M.; Gunther, D.; Stark, W.J. Oxide Nanoparticle Uptake in Human Lung Fibroblasts: Effects of Particle Size, Agglomeration, and Diffusion at Low Concentrations. Environ. Sci. Technol. 2005, 39, 9370–9376.
  65. Studer, A.M.; Limbach, L.K.; Van Duc, L.; Krumeich, F.; Athanassiou, E.K.; Gerber, L.C.; Moch, H.; Stark, W.J. Nanoparticle cytotoxicity depends on intracellular solubility: Comparison of stabilized copper metal and degradable copper oxide nanoparticles. Toxicol. Lett. 2010, 197, 169–174.
  66. Treuel, L.; Jiang, X.; Nienhaus, G.U. New views on cellular uptake and trafficking of manufactured nanoparticles. J. R. Soc. Interface 2013, 10, 20120939.
  67. Ji, Z.; Wang, X.; Zhang, H.; Lin, S.; Meng, H.; Sun, B.; George, S.; Xia, T.; Nel, A.E.; Zink, J.I. Designed synthesis of CeO2 nanorods and nanowires for studying toxicological effects of high aspect ratio nanomaterials. ACS Nano 2012, 6, 5366–5380.
  68. Jacob, S.J.P.; Mohammed, H.; Murali, K.; Kamarudeen, M. Synthesis of silver nanorods using Coscinium fenestratum extracts and its cytotoxic activity against Hep-2 cell line. Colloids Surf. B. Biointerfaces 2012, 98, 7–11.
  69. Rai, M.K.; Deshmukh, S.D.; Ingle, A.P.; Gade, A.K. Silver nanoparticles: The powerful nanoweapon against multidrug-resistant bacteria. J. Appl. Microbiol. 2012, 112, 841–852.
  70. Haider, A.; Kang, I.-K. Preparation of Silver Nanoparticles and Their Industrial and Biomedical Applications: A Comprehensive Review. Adv. Mater. Sci. Eng. 2015, 2015, e165257.
  71. Rauwel, P.; Rauwel, E.; Ferdov, S.; Singh, M.P. Silver Nanoparticles: Synthesis, Properties, and Applications. Adv. Mater. Sci. Eng. 2015, 2015, e624394.
  72. Tubert-Brohman, I.; Sherman, W.; Repasky, M.; Beuming, T. Improved Docking of Polypeptides with Glide. J. Chem. Inf. Model. 2013, 53, 1689–1699.
  73. Li, Y.; Dong, Y.; Yang, Y.; Yu, P.; Zhang, Y.; Hu, J.; Li, T.; Zhang, X.; Liu, X.; Xu, Q.; et al. Rational Design of Silver Gradient for Studying Size Effect of Silver Nanoparticles on Contact Killing. ACS Biomater. Sci. Eng. 2019, 5, 425–431.
  74. Ivanova, E.P.; Hasan, J.; Webb, H.K.; Truong, V.K.; Watson, G.S.; Watson, J.A.; Baulin, V.A.; Pogodin, S.; Wang, J.Y.; Tobin, M.J.; et al. Natural bactericidal surfaces: Mechanical rupture of pseudomonas aeruginosa cells by cicada wings. Small 2012, 8, 2489–2494.
  75. Pogodin, S.; Hasan, J.; Baulin, V.A.; Webb, H.K.; Truong, V.K.; Phong Nguyen, T.H.; Boshkovikj, V.; Fluke, C.J.; Watson, G.S.; Watson, J.A.; et al. Biophysical model of bacterial cell interactions with nanopatterned cicada wing surfaces. Biophys. J. 2013, 104, 835–840.
  76. Johannes, L.; Mayor, S. Induced domain formation in endocytic invagination, lipid sorting, and scission. Cell 2010, 142, 507–510.
  77. Silhavy, T.J.; Kahne, D.; Walker, S. The Bacterial Cell Envelope. Cold Spring Harb Perspect. Biol. 2010, 2, 1–16.
  78. Fuerst, J.A.; Sagulenko, E. Protein uptake by bacteria. Commun. Integr. Biol. 2010, 3, 572–575.
  79. Hajipour, M.J.; Fromm, K.M.; Akbar Ashkarran, A.; de Jimenez Aberasturi, D.; de Larramendi, I.R.; Rojo, T.; Serpooshan, V.; Parak, W.J.; Mahmoudi, M. Antibacterial properties of nanoparticles. Trends Biotechnol. 2012, 30, 499–511.
  80. Nel, A.; Xia, T.; Mädler, L.; Li, N. Toxic potential of materials at the nanolevel. Science 2006, 311, 622–627.
  81. Xia, Q.; Hwang, H.-M.; Ray, P.C.; Yu, H. Mechanisms of nanotoxicity: Generation of reactive oxygen species. J. Food Drug Anal. 2014, 22, 64–75.
  82. Walters, C.; Pool, E.; Somerset, V. Nanotoxicology: A Review. In Toxicology—New Aspects to This Scientific Conundrum; InTech: London, UK, 2016.
  83. Lewinski, N.; Colvin, V.; Drezek, R. Cytotoxicity of Nanoparticles. Small 2008, 4, 26–49.
  84. Vincent, M.; Duval, R.E.; Hartemann, P.; Engels-Deutsch, M. Contact killing and antimicrobial properties of copper. J. Appl. Microbiol. 2018, 124, 1032–1046.
  85. Mathews, S.; Hans, M.; Mücklich, F.; Solioz, M. Contact killing of bacteria on copper is suppressed if bacterial-metal contact is prevented and is induced on iron by copper ions. Appl. Environ. Microbiol. 2013, 79, 2605–2611.
  86. Sondi, I.; Salopek-Sondi, B. Silver nanoparticles as antimicrobial agent: A case study on E. coli as a model for Gram-negative bacteria. J. Colloid Interface Sci. 2004, 275, 177–182.
  87. Hans, M.; Mathews, S.; Mücklich, F.; Solioz, M. Physicochemical properties of copper important for its antibacterial activity and development of a unified model. Biointerphases 2016, 11, 018902.
  88. Vincent, M.; Hartemann, P.; Engels-Deutsch, M. Antimicrobial applications of copper. Int. J. Hyg. Environ. Health 2016, 219, 585–591.
  89. Slavin, Y.N.; Asnis, J.; Häfeli, U.O.; Bach, H. Metal nanoparticles: Understanding the mechanisms behind antibacterial activity. J. Nanobiotechnol. 2017, 15, 65.
  90. Tao, B.; Lin, C.; Deng, Y.; Yuan, Z.; Shen, X.; Chen, M.; He, Y.; Peng, Z.; Hu, Y.; Cai, K. Copper-nanoparticle-embedded hydrogel for killing bacteria and promoting wound healing with photothermal therapy. J. Mater. Chem. B 2019, 7, 2534–2548.
  91. Agnihotri, S.; Mukherji, S.; Mukherji, S. Immobilized silver nanoparticles enhance contact killing and show highest efficacy: Elucidation of the mechanism of bactericidal action of silver. Nanoscale 2013, 5, 7328.
  92. Li, Z.; Lee, D.; Sheng, X.; Cohen, R.E.; Rubner, M.F. Two-Level Antibacterial Coating with Both Release-Killing and Contact-Killing Capabilities. Langmuir 2006, 22, 9820–9823.
  93. Linklater, D.P.; Baulin, V.A.; Juodkazis, S.; Crawford, R.J.; Stoodley, P.; Ivanova, E.P. Mechano-bactericidal actions of nanostructured surfaces. Nat. Rev. Microbiol. 2021, 19, 8–22.
  94. Eleraky, N.E.; Allam, A.; Hassan, S.B.; Omar, M.M. Nanomedicine fight against antibacterial resistance: An overview of the recent pharmaceutical innovations. Pharmaceutics 2020, 12, 142.
  95. Horikoshi, S.; Serpone, N. Microwaves in Nanoparticle Synthesis: Fundamentals and Applications; Wiley-VCH: Weinheim, Germany, 2013; ISBN 9783527331970.
  96. Salas Orozco, M.F.; Niño-Martínez, N.; Martínez-Castañón, G.A.; Méndez, F.T.; Ruiz, F. Molecular mechanisms of bacterial resistance to metal and metal oxide nanoparticles. Int. J. Mol. Sci. 2019, 20, 2808.
  97. Reyes-Esparza, J.; Martínez-Mena, A.; Gutiérrez-Sancha, I.; Rodríguez-Fragoso, P.; Cruz, G.G.; Mondragón, R.; Rodríguez-Fragoso, L. Synthesis, characterization and biocompatibility of cadmium sulfide nanoparticles capped with dextrin for in vivo and in vitro imaging application. J. Nanobiotechnology 2015, 13, 1–14.
  98. Abo-Zeid, Y.; Williams, G.R. The potential anti-infective applications of metal oxide nanoparticles: A systematic review. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnology 2020, 12, 1–36.
  99. Xin, Q.; Shah, H.; Nawaz, A.; Xie, W.; Akram, M.Z.; Batool, A.; Tian, L.; Jan, S.U.; Boddula, R.; Guo, B.; et al. Antibacterial Carbon-Based Nanomaterials. Adv. Mater. 2019, 31, 1–15.
  100. Kakkar, A.; Traverso, G.; Farokhzad, O.C.; Weissleder, R.; Langer, R. Evolution of macromolecular complexity in drug delivery systems. Nat. Rev. Chem. 2017, 1, 63.
  101. Ishihara, K.; Chen, W.; Liu, Y.; Tsukamoto, Y.; Inoue, Y. Cytocompatible and multifunctional polymeric nanoparticles for transportation of bioactive molecules into and within cells. Sci. Technol. Adv. Mater. 2016, 17, 300–312.
  102. Miao, Q.; Xie, C.; Zhen, X.; Lyu, Y.; Duan, H.; Liu, X.; Jokerst, J.V.; Pu, K. Molecular afterglow imaging with bright, biodegradable polymer nanoparticles. Nat. Biotechnol. 2017, 35, 1102.
  103. Pu, K.; Chattopadhyay, N.; Rao, J. Recent advances of semiconducting polymer nanoparticles in in vivo molecular imaging. J. Control. Release 2016, 240, 312–322.
  104. Kairdolf, B.A.; Qian, X.; Nie, S. Bioconjugated Nanoparticles for Biosensing, In Vivo Imaging, and Medical Diagnostics. Anal. Chem. 2017, 89, 1015–1031.
  105. Van Rijt, S.; Habibovic, P. Enhancing regenerative approaches with nanoparticles. J. R. Soc. Interface 2017, 14.
  106. Lam, S.J.; Wong, E.H.H.; Boyer, C.; Qiao, G.G. Antimicrobial polymeric nanoparticles. Prog. Polym. Sci. 2018, 76, 40–64.
  107. Korschelt, K.; Tahir, M.N.; Tremel, W. A Step into the Future: Applications of Nanoparticle Enzyme Mimics. Chemistry 2018, 24, 9703–9713.
  108. Cao, F.; Zhang, L.; Wang, H.; You, Y.; Wang, Y.; Gao, N.; Ren, J.; Qu, X. Defect-Rich Adhesive Nanozymes as Efficient Antibiotics for Enhanced Bacterial Inhibition. Angew. Chemie Int. Ed. 2019, 58, 16236–16242.
  109. Singh, S. Nanomaterials exhibiting enzyme-like properties (Nanozymes): Current advances and future perspectives. Front. Chem. 2019, 7, 1–10.
  110. Meng, Y.; Li, W.; Pan, X.; Gadd, G.M. Applications of nanozymes in the environment. Environ. Sci. Nano 2020, 7, 1305–1318.
  111. Gao, F.; Shao, T.; Yu, Y.; Xiong, Y.; Yang, L. Surface-bound reactive oxygen species generating nanozymes for selective antibacterial action. Nat. Commun. 2021, 12, 1–18.
  112. Yang, D.; Chen, Z.; Gao, Z.; Tammina, S.K.; Yang, Y. Nanozymes used for antimicrobials and their applications. Colloids Surfaces B Biointerfaces 2020, 195, 111252.
  113. Rao, J.P.; Geckeler, K.E. Polymer nanoparticles: Preparation techniques and size-control parameters. Prog. Polym. Sci. 2011, 36, 887–913.
  114. Forier, K.; Raemdonck, K.; De Smedt, S.C.; Demeester, J.; Coenye, T.; Braeckmans, K. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J. Control. Release 2014, 190, 607–623.
  115. Gupta, A.; Landis, R.F.; Li, C.H.; Schnurr, M.; Das, R.; Lee, Y.W.; Yazdani, M.; Liu, Y.; Kozlova, A.; Rotello, V.M. Engineered Polymer Nanoparticles with Unprecedented Antimicrobial Efficacy and Therapeutic Indices against Multidrug-Resistant Bacteria and Biofilms. J. Am. Chem. Soc. 2018, 140, 12137–12143.
  116. Alqahtani, F.Y.; Aleanizy, F.S.; El Tahir, E.; Alhabib, H.; Alsaif, R.; Shazly, G.; Alqahtani, H.; Alsarra, I.A.; Mahdavi, J. Antibacterial activity of chitosan nanoparticles against pathogenic N. gonorrhoea. Int. J. Nanomed. 2020, 15, 7877–7887.
  117. Alqahtani, F.Y.; Aleanizy, F.S.; El Tahir, E.; Alquadeib, B.T.; Alsarra, I.A.; Alanazi, J.S.; Abdelhady, H.G. Preparation, characterization, and antibacterial activity of diclofenac-loaded chitosan nanoparticles. Saudi Pharm. J. 2019, 27, 82–87.
  118. Divya, K.; Vijayan, S.; George, T.K.; Jisha, M.S. Antimicrobial properties of chitosan nanoparticles: Mode of action and factors affecting activity. Fibers Polym. 2017, 18, 221–230.
  119. Smiechowicz, E.; Niekraszewicz, B.; Kulpinski, P.; Dzitko, K. Antibacterial composite cellulose fibers modified with silver nanoparticles and nanosilica. Cellulose 2018, 25, 3499–3517.
  120. Barud, H.S.; Regiani, T.; Marques, R.F.C.; Lustri, W.R.; Messaddeq, Y.; Ribeiro, S.J.L. Antimicrobial bacterial cellulose-silver nanoparticles composite membranes. J. Nanomater. 2011, 2011.
  121. Mei, L.; Cao, F.; Zhang, L.; Xu, J.; Xu, Z.; Yu, Y.; Zhang, X.; Shi, Y.; Li, X.; Cheng, K.; et al. Ag-Conjugated graphene quantum dots with blue light-enhanced singlet oxygen generation for ternary-mode highly-efficient antimicrobial therapy. J. Mater. Chem. B 2020, 8, 1371–1382.
  122. Dong, X.; Liang, W.; Meziani, M.J.; Sun, Y.P.; Yang, L. Carbon dots as potent antimicrobial agents. Theranostics 2020, 10, 671–686.
  123. Shah, S.; Gaikwad, S.; Nagar, S.; Kulshrestha, S.; Vaidya, V.; Nawani, N.; Pawar, S. Biofilm inhibition and anti-quorum sensing activity of phytosynthesized silver nanoparticles against the nosocomial pathogen Pseudomonas aeruginosa. Biofouling 2019, 35, 34–49.
  124. Baptista, P.V.; McCusker, M.P.; Carvalho, A.; Ferreira, D.A.; Mohan, N.M.; Martins, M.; Fernandes, A.R. Nano-strategies to fight multidrug resistant bacteria—“A Battle of the Titans”. Front. Microbiol. 2018, 9, 1–26.
  125. Arango-Santander, S.; Pelaez-Vargas, A.; Freitas, S.C.; García, C. A novel approach to create an antibacterial surface using titanium dioxide and a combination of dip-pen nanolithography and soft lithography. Sci. Rep. 2018, 8, 1–10.
  126. Hussain Bhat, A.; Khan, I.; Jawaid, M.; Suliman, F.O.; Al-Lawati, H.; Muhamed, S.; Editors, A.-K. Advanced Structured Materials. In Nanomaterials for Healthcare, Energy and Environment; Springer: Singapore; ISBN 9789811398322.
  127. Annunziato, G. Strategies to overcome antimicrobial resistance (AMR) making use of non-essential target inhibitors: A review. Int. J. Mol. Sci. 2019, 20, 5844.
  128. Díaz, C.; Schilardi, P.L.; Salvarezza, R.C.; De Mele, M.F.L. Nano/microscale order affects the early stages of biofilm formation on metal surfaces. Langmuir 2007, 23, 11206–11210.
  129. Behravan, M.; Hossein Panahi, A.; Naghizadeh, A.; Ziaee, M.; Mahdavi, R.; Mirzapour, A. Facile green synthesis of silver nanoparticles using Berberis vulgaris leaf and root aqueous extract and its antibacterial activity. Int. J. Biol. Macromol. 2019, 124, 148–154.
  130. Bhardwaj, K.A.; Vinothkumar, K.; Rajpara, N. Bacterial Quorum Sensing Inhibitors: Attractive Alternatives for Control of Infectious Pathogens Showing Multiple Drug Resistance. Recent Pat. Antiinfect. Drug Discov. 2013, 8, 68–83.
  131. Rutherford, S.T.; Bassler, B.L. Bacterial quorum sensing: Its role in virulence and possibilities for its control. Cold Spring Harb. Perspect. Med. 2012, 2.
  132. Sajid, M.; Khan, M.S.A.; Cameotra, S.S.; Ahmad, I. Drug Delivery Systems That Eradicate and/or Prevent Biofilm Formation. In Antibiofilm Agents; Springer: Berlin/Heidelberg, Germany, 2014.
  133. Khan, M.S.A.; Alshehrei, F.; Al-Ghamdi, S.B.; Bamaga, M.A.; Al-Thubiani, A.S.; Alam, M.Z. Virulence and biofilms as promising targets in developing antipathogenic drugs against candidiasis. Futur. Sci. OA 2020, 6.
  134. Qais, F.A.; Khan, M.S.; Ahmad, I. Nanoparticles as quorum sensing inhibitor: Prospects and limitations. Biotechnol. Appl. Quor. Sens. Inhib. 2018, 227–244.
  135. Srivastava, P.; Kowshik, M. Mechanisms of metal resistance and homeostasis in Haloarchaea. Archaea 2013, 2013.
  136. Salas-Orozco, M.; Niño-Martínez, N.; Martínez-Castañón, G.A.; Méndez, F.T.; Jasso, M.E.C.; Ruiz, F. Mechanisms of resistance to silver nanoparticles in endodontic bacteria: A literature review. J. Nanomater. 2019, 2019.
  137. Zhang, R.; Carlsson, F.; Edman, M.; Hummelgård, M.; Jonsson, B.G.; Bylund, D.; Olin, H. Escherichia coli Bacteria Develop Adaptive Resistance to Antibacterial ZnO Nanoparticles. Adv. Biosyst. 2018, 2, 1–7.
  138. Siemer, S.; Westmeier, D.; Barz, M.; Eckrich, J.; Wünsch, D.; Seckert, C.; Thyssen, C.; Schilling, O.; Hasenberg, M.; Pang, C.; et al. Biomolecule-corona formation confers resistance of bacteria to nanoparticle-induced killing: Implications for the design of improved nanoantibiotics. Biomaterials 2019, 192, 551–559.
  139. De Lima, R.; Seabra, A.B.; Durán, N. Silver nanoparticles: A brief review of cytotoxicity and genotoxicity of chemically and biogenically synthesized nanoparticles. J. Appl. Toxicol. JAT 2012, 32, 867–879.
  140. Hendry, A.T.; Stewart, I.O. Silver-resistant Enterobacteriaceae from hospital patients. Can. J. Microbiol. 1979, 25, 915–921.
  141. Li, X.Z.; Nikaido, H.; Williams, K.E. Silver-resistant mutants of Escherichia coli display active efflux of Ag+ and are deficient in porins. J. Bacteriol. 1997, 179, 6127–6132.
  142. Gupta, A.; Silver, S. Silver as a biocide: Will resistance become a problem? Nat. Biotechnol. 1998, 16, 888.
  143. Graves, J.L.; Tajkarimi, M.; Cunningham, Q.; Campbell, A.; Nonga, H.; Harrison, S.H.; Barrick, J.E. Rapid evolution of silver nanoparticle resistance in Escherichia coli. Front. Genet. 2015, 5, 1–13.
  144. Hachicho, N.; Hoffmann, P.; Ahlert, K.; Heipieper, H.J. Effect of silver nanoparticles and silver ions on growth and adaptive response mechanisms of Pseudomonas putida mt-2. FEMS Microbiol. Lett. 2014, 355, 71–77.
  145. Cui, L.; Wang, X.; Huang, D.; Zhao, Y.; Feng, J.; Lu, Q.; Pu, Q.; Wang, Y.; Cheng, G.; Wu, M.; et al. CRISPR-cas3 of Salmonella upregulates bacterial biofilm formation and virulence to host cells by targeting quorum-sensing systems. Pathogens 2020, 9, 53.
  146. Gholizadeh, P.; Köse, Ş.; Dao, S.; Ganbarov, K.; Tanomand, A.; Dal, T.; Aghazadeh, M.; Ghotaslou, R.; Rezaee, M.A.; Yousefi, B.; et al. How CRISPR-Cas system could be used to combat antimicrobial resistance. Infect. Drug Resist. 2020, 13, 1111–1121.
  147. Valentin, E.; Bottomley, A.L.; Chilambi, G.S.; Harry, E.J.; Amal, R.; Sotiriou, G.A.; Rice, S.A.; Gunawan, C. Heritable nanosilver resistance in priority pathogen: A unique genetic adaptation and comparison with ionic silver and antibiotics. Nanoscale 2020, 12, 2384–2392.
  148. Faghihzadeh, F.; Anaya, N.M.; Astudillo-Castro, C.; Oyanedel-Craver, V. Kinetic, metabolic and macromolecular response of bacteria to chronic nanoparticle exposure in continuous culture. Environ. Sci. Nano 2018, 5, 1386–1396.
  149. Finley, P.J.; Norton, R.; Austin, C.; Mitchell, A.; Zank, S.; Durham, P. Unprecedented silver resistance in clinically isolated Enterobacteriaceae: Major implications for burn and wound management. Antimicrob. Agents Chemother. 2015, 59, 4734–4741.
  150. Matuła, K.; Richter, Ł.; Janczuk-Richter, M.; Nogala, W.; Grzeszkowiak, M.; Peplińska, B.; Jurga, S.; Wyroba, E.; Suski, S.; Bilski, H.; et al. Phenotypic plasticity of Escherichia coli upon exposure to physical stress induced by ZnO nanorods. Sci. Rep. 2019, 9, 1–12.
  151. Liu, S.B.; Ng, A.K.; Xu, R.; Wei, J.; Tan, C.M.; Yang, Y.H.; Chen, Y.Y.; Kang, S.; Pinault, M.; Pfefferle, L.D.; et al. Antibacterial action of dispersed single-walled carbon nanotubes on Escherichia coli and Bacillus subtilis investigated by atomic force microscopy. Nanoscale 2010, 2, 2744.
  152. Baym, M.; Lieberman, T.D.; Kelsic, E.D.; Chait, R.; Gross, R.; Yelin, I.; Kishony, R. Spatiotemporal microbial evolution on antibiotic landscapes. Science 2016, 353, 1147–1151.
  153. Zhang, Q.; Lambert, G.; Liao, D.; Kim, H.; Robin, K.; Tung, C.K.; Pourmand, N.; Austin, R.H. Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments. Science 2011, 333, 1764–1767.
  154. Moghadam, M.T.; Amirmozafari, N.; Shariati, A.; Hallajzadeh, M.; Mirkalantari, S.; Khoshbayan, A.; Jazi, F.M. How phages overcome the challenges of drug resistant bacteria in clinical infections. Infect. Drug Resist. 2020, 13, 45–61.
  155. Brives, C.; Pourraz, J. Phage therapy as a potential solution in the fight against AMR: Obstacles and possible futures. Palgrave Commun. 2020, 6, 1–11.
  156. Hay, I.D.; Lithgow, T. Filamentous phages: Masters of a microbial sharing economy. EMBO Rep. 2019, 20.
  157. Pirnay, J.P. Phage Therapy in the Year 2035. Front. Microbiol. 2020, 11, 1–8.
  158. Wright, A.; Hawkins, C.H.; Änggård, E.E.; Harper, D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; A preliminary report of efficacy. Clin. Otolaryngol. 2009, 34, 349–357.
  159. Leitner, L.; Ujmajuridze, A.; Chanishvili, N.; Goderdzishvili, M.; Chkonia, I.; Rigvava, S.; Chkhotua, A.; Changashvili, G.; McCallin, S.; Schneider, M.P.; et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: A randomised, placebo-controlled, double-blind clinical trial. Lancet Infect. Dis. 2020, 3099, 1–10.
  160. Speck, P.; Smithyman, A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol. Lett. 2015, 363, 1–5.
  161. Aslam, S.; Lampley, E.; Wooten, D.; Karris, M.; Benson, C.; Strathdee, S.; Schooley, R.T. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect. Dis. 2020, 7.
  162. Voelker, R. FDA Approves Bacteriophage Trial. JAMA 2019, 321, 638.
  163. Cisek, A.A.; Dąbrowska, I.; Gregorczyk, K.P.; Wyżewski, Z. Phage Therapy in Bacterial Infections Treatment: One Hundred Years after the Discovery of Bacteriophages. Curr. Microbiol. 2017, 74, 277–283.
  164. Gordillo Altamirano, F.L.; Barr, J.J. Phage therapy in the postantibiotic era. Clin. Microbiol. Rev. 2019, 32, 1–25.
  165. Gazeev, S. Fagterapi och dess Tillämpning inom Veterinärmedicin. In Applications of Phage Therapy in Veterinary Medicine Applications of Phage Therapy in Veterinary Medicine; Swedish University of Agricultural Sciences: Uppsala, Sweden, 2018; p. 18.
  166. Smirnov, D.D.; Kapustin, A.V.; Yakimova, E.A.; Savinov, V.A.; Laishevtsev, A.I. Perspectives of the use of bacteriophages in agriculture, food and processing industries. IOP Conf. Ser. Earth Environ. Sci. 2020, 548.
  167. Endersen, L.; Coffey, A. The use of bacteriophages for food safety. Curr. Opin. Food Sci. 2020, 36, 1–8.
  168. Summers, W.C. The strange history of phage therapy. Bacteriophage 2012, 2, 130–133.
  169. Lin, D.M.; Koskella, B.; Lin, H.C. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest. Pharmacol. Ther. 2017, 8, 162.
  170. Van Belleghem, J.D.; Dąbrowska, K.; Vaneechoutte, M.; Barr, J.J.; Bollyky, P.L. Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses 2019, 11, 10.
  171. Lehti, T.A.; Pajunen, M.I.; Skog, M.S.; Finne, J. Internalization of a polysialic acid-binding Escherichia coli bacteriophage into eukaryotic neuroblastoma cells. Nat. Commun. 2017.
  172. Di Giovine, M.; Salone, B.; Martina, Y.; Amati, V.; Zambruno, G.; Cundari, E.; Failla, C.M.; Saggio, I. Binding properties, cell delivery, and gene transfer of adenoviral penton base displaying bacteriophage. Virology 2001.
  173. Weber-Dabrowska, B.; Zimecki, M.; Mulczyk, M. Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Arch. Immunol. Ther. Exp. 2000, 48, 31–37.
  174. Park, K.; Cha, K.E.; Myung, H. Observation of inflammatory responses in mice orally fed with bacteriophage T7. J. Appl. Microbiol. 2014.
  175. Szermer-Olearnik, B.; Boratyński, J. Removal of endotoxins from bacteriophage preparations by extraction with organic solvents. PLoS ONE 2015.
  176. Manohar, P.; Tamhankar, A.J.; Leptihn, S.; Ramesh, N. Pharmacological and Immunological Aspects of Phage Therapy. Infect. Microbes Dis. 2019, 1, 34–42.
  177. Maciejewska, B.; Olszak, T.; Drulis-Kawa, Z. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: An ambitious and also a realistic application? Appl. Microbiol. Biotechnol. 2018, 102, 2563–2581.
  178. Łusiak-Szelachowska, M.; Zaczek, M.; Weber-Dabrowska, B.; Miȩdzybrodzki, R.; Kłak, M.; Fortuna, W.; Letkiewicz, S.; Rogóz, P.; Szufnarowski, K.; Jończyk-Matysiak, E.; et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 2014, 27, 295–304.
  179. Górski, A.; Miedzybrodzki, R.; Borysowski, J.; Dabrowska, K.; Wierzbicki, P.; Ohams, M.; Korczak-Kowalska, G.; Olszowska-Zaremba, N.; Łusiak-Szelachowska, M.; Kłak, M.; et al. Phage as a Modulator of Immune Responses. Practical Implications for Phage Therapy. Adv. Virus Res. 2012, 83, 41–47.
  180. Hess, K.L.; Jewell, C.M. Phage display as a tool for vaccine and immunotherapy development. Bioeng. Transl. Med. 2020, 5, 1–15.
  181. Vukotic, G.; Obradovic, M.; Novovic, K.; Di Luca, M.; Jovcic, B.; Fira, D.; Neve, H.; Kojic, M.; McAuliffe, O. Characterization, Antibiofilm, and Depolymerizing Activity of Two Phages Active on Carbapenem-Resistant Acinetobacter baumannii. Front. Med. 2020, 7, 1–12.
  182. Ferriol-González, C.; Domingo-Calap, P. Phages for Biofilm Removal. Antibiotics 2020, 9, 268.
  183. Tagliaferri, T.L.; Jansen, M.; Horz, H.P. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy. Front. Cell. Infect. Microbiol. 2019, 9, 22.
  184. Rodriguez-Gonzalez, R.A.; Leung, C.Y.; Chan, B.K.; Turner, P.E.; Weitz, J.S. Quantitative Models of Phage-Antibiotics Combination Therapy. BioRxiv 2019, 5.
  185. Morrisette, T.; Kebriaei, R.; Morales, S.; Rybak, M.J. Bacteriophage-Antibiotic Combinations: A Promising Alternative for Refractory Infections? Contagion 2020, 5, 1.
  186. Liu, C.G.; Green, S.I.; Min, L.; Clark, J.R.; Salazar, K.C.; Terwilliger, A.L.; Kaplan, H.B.; Trautner, B.W.; Ramig, R.F.; Maresso, A.W. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. MBio 2020, 11, 1–19.
  187. Paczesny, J.; Richter, Ł.; Hołyst, R. Recent progress in the detection of bacteria using bacteriophages: A review. Viruses 2020, 12, 845.
  188. Banuelos, S.; Gulbudak, H.; Horn, M.A.; Huang, Q.; Nandi, A.; Ryu, H.; Segal, R. Investigating the impact of combination phage and antibiotic therapy: A modeling study. BioRxiv 2020.
  189. Górski, A.; Borysowski, J.; Międzybrodzki, R. Phage therapy: Towards a successful clinical trial. Antibiotics 2020, 9, 827.
  190. Peng, H.; Borg, R.E.; Dow, L.P.; Pruitt, B.L.; Chen, I.A. Controlled phage therapy by photothermal ablation of specific bacterial species using gold nanorods targeted by chimeric phages. Proc. Natl. Acad. Sci. USA 2020, 117, 1951–1961.
  191. Paczesny, J.; Bielec, K. Application of bacteriophages in nanotechnology. Nanomaterials 2020, 10, 944.
  192. Quispe-Tintaya, W. Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine. Physiol. Behav. 2017, 176, 139–148.
  193. Labrie, S.J.; Samson, J.E.; Moineau, S. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 2010, 8, 317–327.
  194. Foster, T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005, 3, 948–958.
  195. Seed, K.D. Battling Phages: How Bacteria Defend against Viral Attack. PLoS Pathog. 2015, 11, 1–5.
  196. Destoumieux-Garzón, D.; Duquesne, S.; Peduzzi, J.; Goulard, C.; Desmadril, M.; Letellier, L.; Rebuffat, S.; Boulanger, P. The iron-siderophore transporter FhuA is the receptor for the antimicrobial peptide microcin J25: Role of the microcin Val11-Pro16 β-hairpin region in the recognition mechanism. Biochem. J. 2005, 389, 869–876.
  197. Vasu, K.; Nagaraja, V. Diverse Functions of Restriction-Modification Systems in Addition to Cellular Defense. Microbiol. Mol. Biol. Rev. 2013, 77, 53–72.
  198. Goldfarb, T.; Sberro, H.; Weinstock, E.; Cohen, O.; Doron, S.; Charpak-Amikam, Y.; Afik, S.; Ofir, G.; Sorek, R. BREX is a novel phage resistance system widespread in microbial genomes. EMBO J. 2015, 34, 169–183.
  199. Chaudhary, K. BacteRiophage EXclusion (BREX): A novel anti-phage mechanism in the arsenal of bacterial defense system. J. Cell. Physiol. 2018, 233, 771–773.
  200. Ofir, G.; Melamed, S.; Sberro, H.; Mukamel, Z.; Silverman, S.; Yaakov, G.; Doron, S.; Sorek, R. DISARM is a widespread bacterial defence system with broad anti-phage activities. Nat. Microbiol. 2018, 3, 90–98.
  201. Swarts, D.C.; Jore, M.M.; Westra, E.R.; Zhu, Y.; Janssen, J.H.; Snijders, A.P.; Wang, Y.; Patel, D.J.; Berenguer, J.; Brouns, S.J.J.; et al. DNA-guided DNA interference by a prokaryotic Argonaute. Nature 2014, 507, 258–261.
  202. Xiong, L.; Liu, S.; Chen, S.; Xiao, Y.; Zhu, B.; Gao, Y.; Zhang, Y.; Chen, B.; Luo, J.; Deng, Z.; et al. A new type of DNA phosphorothioation-based antiviral system in archaea. Nat. Commun. 2019, 10, 1–11.
  203. Kronheim, S.; Daniel-Ivad, M.; Duan, Z.; Hwang, S.; Wong, A.I.; Mantel, I.; Nodwell, J.R.; Maxwell, K.L. A chemical defence against phage infection. Nature 2018, 564, 283–286.
  204. Phumyen, A.; Jantasorn, S.; Jumnainsong, A.; Leelayuwat, C. Doxorubicin-conjugated bacteriophages carrying anti-MHC class I chain-related A for targeted cancer therapy in vitro. Onco. Targets. Ther. 2014, 7, 2183–2195.
  205. Lau, R.K.; Ye, Q.; Birkholz, E.A.; Berg, K.R.; Patel, L.; Mathews, I.T.; Watrous, J.D.; Ego, K.; Whiteley, A.T.; Lowey, B.; et al. Structure and Mechanism of a Cyclic Trinucleotide-Activated Bacterial Endonuclease Mediating Bacteriophage Immunity. Mol. Cell 2020, 77, 723–733.e6.
  206. Millman, A.; Melamed, S.; Amitai, G.; Sorek, R. Diversity and classification of cyclic-oligonucleotide-based anti-phage signalling systems. Nat. Microbiol. 2020, 5, 1608–1615.
  207. Hampton, H.G.; Watson, B.N.J.; Fineran, P.C. The arms race between bacteria and their phage foes. Nature 2020, 577, 327–336.
  208. Boyaval, P.; Moineau, S.; Romero, D.A.; Horvath, P. Against Viruses in Prokaryotes. Science 2007, 315, 1709–1712.
  209. Broniewski, J.M.; Chisnall, M.A.W.; Molin, N.; Westra, E.R. The effect of Quorum sensing inhibitors on the evolution of CRISPR-based phage immunity in Pseudomonas aeruginosa. ISME J. 2021.
  210. Shehreen, S.; Chyou, T.Y.; Fineran, P.C.; Brown, C.M. Genome-wide correlation analysis suggests different roles of CRISPR-Cas systems in the acquisition of antibiotic resistance genes in diverse species. Philos. Trans. R. Soc. B Biol. Sci. 2019, 374.
  211. Trasanidou, D.; Gerós, A.S.; Mohanraju, P.; Nieuwenweg, A.C.; Nobrega, F.L.; Staals, R.H.J. Keeping crispr in check: Diverse mechanisms of phage-encoded anti-crisprs. FEMS Microbiol. Lett. 2019, 366, 1–14.
  212. Landsberger, M.; Gandon, S.; Meaden, S.; Rollie, C.; Chevallereau, A.; Chabas, H.; Buckling, A.; Westra, E.R.; van Houte, S. Anti-CRISPR Phages Cooperate to Overcome CRISPR-Cas Immunity. Cell 2018, 174, 908–916.e12.
  213. Gussow, A.B.; Park, A.E.; Borges, A.L.; Shmakov, S.A.; Makarova, K.S.; Wolf, Y.I.; Bondy-Denomy, J.; Koonin, E.V. Machine-learning approach expands the repertoire of anti-CRISPR protein families. Nat. Commun. 2020, 11, 1–12.
  214. Matsumoto, D.; Tamamura, H.; Nomura, W. A cell cycle-dependent CRISPR-Cas9 activation system based on an anti-CRISPR protein shows improved genome editing accuracy. Commun. Biol. 2020, 3, 2–3.
  215. Stanley, S.Y.; Borges, A.L.; Chen, K.H.; Swaney, D.L.; Krogan, N.J.; Bondy-Denomy, J.; Davidson, A.R. Anti-CRISPR-Associated Proteins Are Crucial Repressors of Anti-CRISPR Transcription. Cell 2019, 178, 1452–1464.e13.
  216. Rostøl, J.T.; Marraffini, L. (Ph)ighting Phages: How Bacteria Resist Their Parasites. Cell Host Microbe 2019, 25, 184–194.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback